According to Gram Research analysis, atractylenolide I, a compound from the traditional Chinese herb Atractylodes macrocephala, reduced liver damage markers and prevented cell death in mice with fatty liver disease and in laboratory liver cells. The compound activated a protective protein called SIRT1, which reduced cellular stress and inflammation. While these 2026 findings are promising, human studies are needed before this natural compound can be recommended as a treatment for non-alcoholic fatty liver disease.
Researchers discovered that atractylenolide I (AO-I), a natural compound found in a traditional Chinese herb called Atractylodes macrocephala, may help protect the liver from fat-related damage. In studies with mice fed a high-fat diet and in laboratory tests with liver cells, AO-I reduced liver injury markers and prevented cell death by activating a protective protein called SIRT1. The compound worked by reducing stress inside liver cells and preventing harmful inflammation. These findings suggest AO-I could become a natural treatment option for non-alcoholic fatty liver disease (NAFLD), a common condition affecting millions of people worldwide.
Key Statistics
A 2026 research article found that mice treated with atractylenolide I showed significant improvements in liver function markers (ALT and AST enzymes) and reduced fat accumulation in liver tissue compared to untreated mice fed a high-fat diet for 12 weeks.
According to a 2026 study published in Phytotherapy Research, atractylenolide I protected isolated liver cells from palmitate-induced damage by activating the SIRT1 protein, which reduced endoplasmic reticulum stress and prevented harmful inflammatory pathways.
A 2026 mechanistic study demonstrated that atractylenolide I reduced the activation of inflammatory proteins (JNK and p38 MAPK) that are typically elevated in non-alcoholic fatty liver disease, suggesting multiple protective pathways.
Research from 2026 showed that the protective effects of atractylenolide I were dose-dependent in both animal models and cell cultures, with higher doses providing greater protection against fat-related liver damage.
The Quick Take
- What they studied: Whether a natural plant compound called atractylenolide I could protect liver cells from damage caused by excess fat buildup
- Who participated: Laboratory mice fed a high-fat diet for 12 weeks to develop fatty liver disease, plus cultured liver cells exposed to fatty acids in test tubes
- Key finding: Mice treated with the plant compound showed improved liver function tests and less liver damage compared to untreated mice, with the compound reducing harmful fat-related stress inside liver cells
- What it means for you: This research suggests a natural supplement might help people with fatty liver disease, though human studies are still needed to confirm safety and effectiveness before it becomes a standard treatment
The Research Details
The researchers used two complementary approaches to test their hypothesis. First, they created fatty liver disease in laboratory mice by feeding them a high-fat diet for 12 weeks, then gave some mice the plant compound atractylenolide I at different doses while others received no treatment. They measured liver damage markers in the blood and examined liver tissue under a microscope. Second, they conducted laboratory experiments using isolated liver cells, exposing them to palmitate (a type of fat) to simulate lipotoxicity, then treated some cells with the compound to observe protective effects.
This dual approach—combining animal studies with cell-level investigations—allowed researchers to observe both whole-body effects and the specific cellular mechanisms involved. The study included mechanistic investigations to identify exactly how the compound worked, examining specific proteins and cellular stress pathways.
The research design is considered robust because it combined in vivo (whole animal) and in vitro (laboratory cell) models, allowing researchers to validate findings across different biological systems and identify the precise molecular pathways involved in the protective effects.
This research approach matters because fatty liver disease is increasingly common and currently has limited treatment options beyond lifestyle changes. By identifying a natural compound with protective mechanisms, researchers can potentially develop new therapeutic strategies. The mechanistic focus—understanding exactly how the compound works—is important because it helps determine whether the findings might apply to human patients and guides future drug development.
Strengths of this study include the use of both animal models and isolated cell systems, detailed mechanistic investigations identifying specific protective pathways, and measurement of multiple relevant outcomes (liver enzymes, tissue damage, cellular stress markers). The research was published in a peer-reviewed journal specializing in plant-based medicines. Limitations include the use of animal models rather than human subjects, relatively short study duration (12 weeks), and the need for larger-scale human trials to confirm effectiveness and safety in real patients.
What the Results Show
Mice treated with atractylenolide I showed significant improvements in liver function. Blood markers of liver damage (ALT and AST enzymes) decreased substantially in treated mice compared to untreated controls. When researchers examined liver tissue under a microscope, treated mice showed less fat accumulation and less inflammation compared to mice that received no treatment.
In laboratory experiments with isolated liver cells, the compound directly protected cells from palmitate-induced damage, reducing cell death rates. The protective effect was dose-dependent, meaning higher doses of the compound provided greater protection, suggesting a clear biological relationship.
Mechanistic studies revealed that the compound worked by activating a protective protein called SIRT1, which then reduced cellular stress in the endoplasmic reticulum (a cellular structure responsible for protein production). This stress reduction prevented harmful inflammatory pathways from being activated, protecting liver cells from damage.
The research identified that atractylenolide I reduced the activation of specific inflammatory proteins (JNK and p38 MAPK) that are typically elevated in fatty liver disease. The compound also prevented the abnormal splicing of a stress-response protein called XBP1, indicating it reduced overall cellular stress. These secondary findings suggest the compound works through multiple protective mechanisms rather than a single pathway, which may explain its effectiveness.
Previous research has identified SIRT1 as a key protective protein in liver disease, and several studies have shown that activating SIRT1 can improve fatty liver disease outcomes. This study extends that knowledge by identifying a natural compound that activates SIRT1 and demonstrating its effectiveness in a disease model. The findings align with traditional uses of Atractylodes macrocephala in Chinese medicine for liver support, providing scientific validation for historical medical practices.
The study was conducted in mice and laboratory cells, not humans, so results may not directly translate to human patients. The research lasted only 12 weeks, which is relatively short for evaluating long-term safety and effectiveness. The study did not compare atractylenolide I to existing NAFLD treatments or other natural compounds. Human clinical trials would be necessary to determine appropriate dosing, safety profile, and real-world effectiveness before this compound could be recommended as a treatment. Additionally, the exact mechanisms by which the compound is absorbed and processed in the human body remain unknown.
The Bottom Line
Based on current evidence, atractylenolide I shows promise as a potential therapeutic agent for fatty liver disease, but it is not yet ready for clinical use. People with fatty liver disease should continue following established recommendations: maintain a healthy weight, reduce refined carbohydrate and sugar intake, limit alcohol consumption, and exercise regularly. Individuals interested in trying plant-based supplements should consult their healthcare provider before starting any new treatment, as supplements can interact with medications and may not be appropriate for everyone.
This research is most relevant to people with non-alcoholic fatty liver disease (NAFLD), researchers developing new treatments for liver disease, and individuals interested in plant-based medicine. People with existing liver conditions, those taking medications that affect liver function, and pregnant or nursing women should be especially cautious about trying new supplements without medical guidance. Healthcare providers treating NAFLD patients should be aware of this emerging research but should not yet recommend it as a standard treatment.
In animal studies, protective effects appeared within the 12-week treatment period. However, realistic expectations for human use are uncertain at this stage. If this compound advances to human clinical trials, it typically takes 5-10 years of research before a new treatment becomes available to patients. Benefits would likely develop gradually over weeks to months of consistent use, similar to other liver-protective interventions.
Frequently Asked Questions
Can atractylenolide I supplements treat fatty liver disease in humans?
Not yet. While 2026 research shows the compound protected mouse livers and liver cells from fat damage, human clinical trials are still needed to confirm safety and effectiveness. Current standard treatments remain lifestyle changes and medical supervision.
How does atractylenolide I protect the liver from fat damage?
The compound activates a protective protein called SIRT1, which reduces stress inside liver cells and prevents harmful inflammation. This mechanism was demonstrated in both animal studies and laboratory cell experiments in 2026 research.
What is the source of atractylenolide I?
Atractylenolide I is a natural compound extracted from Atractylodes macrocephala, a plant used in traditional Chinese medicine for centuries. The 2026 study validated scientific basis for its historical use in supporting liver health.
Is atractylenolide I safe for people with fatty liver disease?
Safety in humans has not been established. While animal studies showed no reported adverse effects, human clinical trials are necessary to determine appropriate dosing, potential side effects, and interactions with medications before recommending it.
How long would it take to see benefits from atractylenolide I?
Animal studies showed protective effects within 12 weeks, but human timelines are unknown. If approved for human use, benefits would likely develop gradually over weeks to months, similar to other liver-protective treatments.
Want to Apply This Research?
- Users could track liver health markers by logging their ALT and AST enzyme levels from periodic blood tests (typically available through annual physicals or liver function panels), noting the date and values to monitor trends over time
- Users with fatty liver disease could use the app to log daily habits that support liver health: minutes of exercise completed, servings of vegetables consumed, alcohol intake (if applicable), and weight measurements, creating accountability for lifestyle changes that complement any supplement use
- Establish a quarterly check-in system where users record liver function test results from their healthcare provider, track symptom changes (fatigue, abdominal discomfort), and monitor weight trends, creating a comprehensive picture of liver health progression over 6-12 months
This article summarizes research findings and is for educational purposes only. It does not constitute medical advice. Atractylenolide I is not currently approved as a medical treatment for fatty liver disease in most countries. Individuals with non-alcoholic fatty liver disease should consult their healthcare provider before starting any new supplement or treatment. This research was conducted in animals and laboratory cells; human safety and effectiveness have not been established. Do not discontinue prescribed medications or medical treatments based on this information. Pregnant women, nursing mothers, and individuals with existing liver conditions should exercise particular caution and seek professional medical guidance before using any new supplements.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.